Full name

REIMAGINE - A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma

NCT Number
NCT06041386
Geography
US
Non-US
Locations

Belgium, Canada, France, Germany, Italy, Japan, Poland, Spain, United States

Primary Endpoints

Percentage (%) of Participants Achieving 4-Component Clinical Remission at month 12

External Link
https://clinicaltrials.gov/study/NCT06041386
Order
2
Disease
Asthma
Menu title
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Version
ATS 2025
Phase
4
Status
Recruiting